Correlation Between Karyopharm Therapeutics and Summit Therapeutics

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Summit Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Summit Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Summit Therapeutics PLC, you can compare the effects of market volatilities on Karyopharm Therapeutics and Summit Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Summit Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Summit Therapeutics.

Diversification Opportunities for Karyopharm Therapeutics and Summit Therapeutics

0.16

Correlation Coefficient

Karyopharm Therapeutics  Summit Therapeutics

Average diversification

The 3 months correlation between Karyopharm and Summit is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Summit Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Summit Therapeutics PLC and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Summit Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Summit Therapeutics PLC has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Summit Therapeutics go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Summit Therapeutics

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Summit Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 1.63 times less risky than Summit Therapeutics. The stock trades about -0.65 of its potential returns per unit of risk. The Summit Therapeutics PLC is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  1,919  in Summit Therapeutics PLC on September 25, 2024 and sell it today you would lose (52.00) from holding Summit Therapeutics PLC or give up 2.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Summit Therapeutics PLC

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Summit Therapeutics PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's primary indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Karyopharm Therapeutics and Summit Therapeutics

The main advantage of trading using opposite Karyopharm Therapeutics and Summit Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Summit Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Summit Therapeutics will offset losses from the drop in Summit Therapeutics' long position.

The idea behind Karyopharm Therapeutics and Summit Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.